Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2021-12-18 Major Shareholding Noti…
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Acquisition
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition and sale of shares by an acquirer (M/s Growel Remedies Limited) in the target company (Medicamen Biotech Limited). The content includes specifics about shareholding percentages before and after the transaction, mode of acquisition, and dates. This type of filing corresponds to notifications about changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about share acquisition. The length and detail confirm it is not a mere announcement but the actual disclosure document.
2021-12-18 English
Trading Plan under PIT
Regulatory Filings Classification · 100% confidence The document is an intimation filed under Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. It discloses the sale of equity shares by a promoter (Growel Remedies Limited) of Medicamen Biotech Limited. The document includes Form-C disclosure details about the change in shareholding and is addressed to stock exchanges (BSE and NSE). It is a regulatory compliance filing related to insider trading disclosures and shareholding changes by promoters. There are no financial statements, management discussion, or earnings data present. The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS). The document length (12,577 characters) and content confirm it is a full disclosure, not just a brief announcement or certification.
2021-12-18 English
Acquisition
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition of shares by M/s Shivalik Rasayan Limited in Medicamen Biotech Limited, including shareholding percentages before and after acquisition, mode of acquisition, and dates. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or any other type of report but a regulatory disclosure about share acquisition.
2021-12-16 English
Trading Plan under PIT
Major Shareholding Notification Classification · 100% confidence The document is an intimation filed under Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. It discloses the purchase of equity shares by Shivalik Rasayan Limited, a promoter of Medicamen Biotech Limited, from the open market. The document includes Form-C disclosure details about the change in shareholding of a promoter. There are no financial statements, earnings data, or management discussion. The content is a regulatory compliance disclosure related to insider trading and shareholding changes, not a financial report or earnings release. This type of filing corresponds to a Major Shareholding Notification (MRQ) as it reports changes in significant share ownership levels crossing thresholds.
2021-12-16 English
Acquisition
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition and sale of shares by Growel Remedies Limited in Medicamen Biotech Limited, including shareholding percentages before and after the transaction, mode of acquisition, and dates. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or any other report type but a regulatory disclosure about shareholding changes.
2021-12-16 English
Trading Plan under PIT
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the sale of equity shares by a promoter (Growel Remedies Limited) of Medicamen Biotech Limited. It includes details of the shareholding changes and compliance with insider trading regulations. There is no financial performance data, earnings information, or management discussion. The document is a regulatory compliance filing related to insider trading disclosures, not a financial report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS). The document length is sufficient and contains detailed disclosure information, confirming it is not a mere announcement but a regulatory filing.
2021-12-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.